News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bavarian Nordic (BAVA.CO) Presents Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The American Association for Cancer Research Annual Meeting 2014



4/7/2014 9:02:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, April 7, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated data from an NCI sponsored combination study of Bavarian Nordic's active immunotherapy candidate PROSTVAC and ipilimumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Wednesday, April 9, 2014. The data highlights the potential synergy of combining PROSTVAC with an immune checkpoint inhibitor.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES